Welcome to our dedicated page for Innovent Biologi news (Ticker: IVBIY), a resource for investors and traders seeking the latest updates and insights on Innovent Biologi stock.
The news feed for INNOVENT BIOLGCS UNSP/ADR (IVBIY) aggregates company press releases and media updates from Innovent Biologics, Inc., a biopharmaceutical company focused on oncology, cardiovascular and metabolic, autoimmune and ophthalmology diseases. These announcements provide insight into clinical trial progress, regulatory milestones, product approvals and corporate strategy that can influence how investors and observers view IVBIY.
Recent news highlights include multiple updates on mazdutide, a dual GCG/GLP-1 receptor agonist licensed from Eli Lilly for development in China. Innovent has reported National Medical Products Administration approvals for mazdutide in chronic weight management for adults with overweight or obesity and for glycemic control in adults with type 2 diabetes, along with Phase 3 data from the GLORY and DREAMS clinical programs. Other cardiovascular and metabolic pipeline news covers tigulixostat, a xanthine oxidase inhibitor for gout, and IBI3032, an oral GLP-1 receptor agonist with U.S. FDA IND approval for Phase 1 trials.
Oncology news items describe the development of IBI363, a PD-1/IL-2α-bias fusion protein, including U.S. FDA clearance of an IND for a global Phase 3 trial in immunotherapy-resistant squamous non-small cell lung cancer and data presented at major oncology conferences. Additional coverage includes IBI343, an anti-CLDN18.2 ADC with Phase 1 results in gastric/gastroesophageal junction adenocarcinoma published in Nature Medicine and the launch of multi-regional Phase 3 studies.
Investors following IVBIY can use this page to review updates on Innovent’s broader pipeline, such as picankibart for psoriasis, IBI324 for retinal diseases, and other marketed products mentioned in interim results and R&D day communications. Bookmark this news section to monitor how clinical data releases, regulatory decisions and partnership announcements may shape the company’s long-term development and commercialization plans.
Innovent Biologics announced that it will present clinical data on two of its innovative treatments, IBI363 and IBI343, at upcoming conferences in June 2024. IBI363, a PD-1/IL-2 bispecific antibody fusion protein, will be discussed at the ESMO Virtual Plenary on June 13-14, 2024. IBI343, an anti-Claudin18.2 antibody-drug conjugate, will be presented at the ESMO Gastrointestinal Cancers Congress on June 26-29, 2024. The presentations will focus on early-phase clinical studies in patients with advanced solid tumors and gastric/gastro-esophageal junction adenocarcinoma. Dr. Hui Zhou, Senior VP at Innovent, emphasized the potential efficacy and safety of these treatments, highlighting Innovent's commitment to addressing unmet medical needs in cancer therapy.
Innovent Biologics, Inc. announced the successful results of the Phase 3 clinical trial of mazdutide in Chinese patients with type 2 diabetes. Mazdutide demonstrated superior glycaemic control compared to dulaglutide, along with multiple cardiometabolic benefits such as weight loss, improved blood lipid, blood pressure, and liver enzymes. The study included 731 subjects and showed mazdutide's superior glucose-lowering efficacy and weight loss benefits. Mazdutide also displayed favorable safety and tolerability profiles, with gastrointestinal adverse reactions being the most common. The drug is the first GLP-1R/GCGR dual agonist in regulatory review status, with plans for an NDA submission for chronic weight management. Overall, mazdutide showcased promising results in the treatment of type 2 diabetes.
Innovent Biologics, Inc. receives NMPA Breakthrough Therapy Designation for IBI343 as monotherapy for advanced gastric cancer. The designation is based on promising Phase 1 study results showing safety, tolerability, and antitumor activity in advanced GC patients. Innovent plans to conduct a Phase 3 clinical trial soon. The company aims to provide effective third-line treatment options for GC patients in need.
Innovent Biologics, Inc. appoints Dr. Samuel Zhang as Global Chief Business Officer, bringing over 20 years of industry experience. Dr. Zhang will lead global strategy and business development, reporting to Dr. Michael Yu. His expertise includes identifying industry trends, R&D decision-making, and strategic transactions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.